2. Synthesis Engine Andi's "synthesis engine" makes question answering a breeze, while tools to fight spam and bad content keep your search results clean.
AI
-
Andi Search: Conversational AI Search Experience Revolution
By
–
Let's look at how Andi will change your search experience forever. 1. Conversational Interface Andi search works like a conversation where you can ask questions and get pin-pointed answers, rather than just some links. It's like having a smart friend available to you 24X7!
-
Andi: Next Generation Search Engine Powered by AI
By
–
Google search is a thing of the past! Meet Andi, the next generation of search engine that will change the way you find information! (A Thread)
-
Spanish TV Wrongly Credits Elon Musk for Founding Midjourney
By
–
¿Acaban de decir en Zapeando que Midjourney lo ha fundado Elon Musk? Sí… El error es estar yo viendo la TV
-
Microsoft Invests Heavily in AI Through OpenAI Partnership
By
–
Microsoft goes whole hog with AI. // $MSFT @OpenAI // #stocks #investing #AI #machinelearning #OpenAI #ChatGPT
-
Predictive Coding: Deep Learning Beyond Backpropagation
By
–
#TenstorrentTop10: each week Tenstorrent will be highlighting a paper that has inspired our product development. This week: Predictive Coding Towards a Future of Deep Learning Beyond Backpropagation. #predictive #coding #machinelearning #tenstorrent
-
Demand for FLAN-T5 fine-tuning observed
By
–
Yeah, definitely seeing demand for FLAN-T5, though always for fine-tuning.
-
Curie available as ‘curie’ instead of ‘text-curie-001’
By
–
Original pre-trained Curie is available. The model is just “curie” instead of “text-curie-001”.
-
Atomic AI: Science, Business, and Investment Impact Analysis
By
–
We're proud to get to tell Atomic AI's story. @ElliotHershberg & I teamed up on this one to explain the science, the business, the potential impact, and why we invested.
-
Atomic AI Develops RNA Therapeutic Portfolio for Pharma Licensing
By
–
Atomic AI plans to develop its own internal portfolio of hundreds of druggable RNA structures and therapeutic designs in the next few years. Each structure represents the potential for billions in revenue via licensing agreements with pharma companies. As an example: